Beyond tyrosine kinase inhibitors: Combinations and other agents
Tài liệu tham khảo
Deininger, 2009, International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib, Blood (ASH Annual Meeting Abstracts), 114, 1126
Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013, Blood, 122, 872, 10.1182/blood-2013-05-501569
O'Brien, 2003, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N Engl J Med, 348, 994, 10.1056/NEJMoa022457
Druker, 2006, Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia, N Engl J Med, 355, 2408, 10.1056/NEJMoa062867
Mahon, 2010, Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, Lancet Oncol, 11, 1029, 10.1016/S1470-2045(10)70233-3
Ross, 2010, Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR, Leukemia, 24, 1719, 10.1038/leu.2010.185
Hu, 2006, Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice, Proc Natl Acad Sci U S A, 103, 16870, 10.1073/pnas.0606509103
Jamieson, 2008, Chronic myeloid leukemia stem cells, Hematol Am Soc Hematol Educ Program, 436, 10.1182/asheducation-2008.1.436
Rice, 2010, Molecular pathways to CML stem cells, Int J Hematol, 91, 748, 10.1007/s12185-010-0615-8
Zhao, 2009, Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukemia, Nature, 458, 776, 10.1038/nature07737
Bhatia, 2003, Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment, Blood, 101, 4701, 10.1182/blood-2002-09-2780
Chomel, 2000, Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation, Blood, 95, 404, 10.1182/blood.V95.2.404
Talpaz, 1994, Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies, J Clin Invest, 94, 1383, 10.1172/JCI117473
Bocchia, 2008, CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate, Leukemia, 22, 426, 10.1038/sj.leu.2404893
Mustjoki, 2010, Low or undetectable numbers of Philadelphia chromosome-positive leukemic stem cells (Ph(+)CD34(+)CD38(neg)) in chronic myeloid leukemia patients in complete cytogenetic remission after tyrosine kinase inhibitor therapy, Leukemia, 24, 219, 10.1038/leu.2009.190
Nair, 2010, The bone marrow microenvironment as a sanctuary for minimal residual disease in CML, Biochem Pharmacol, 80, 602, 10.1016/j.bcp.2010.04.003
Ben-Neriah, 1986, The chronic myelogenous leukaemia-specific P210 protein is the product of the bcr/abl hybrid gene, Science, 233, 212, 10.1126/science.3460176
Shtivelman, 1985, Fused transcript of abl and bcr genes in chronic myelogenous leukaemia, Nature, 315, 550, 10.1038/315550a0
Smit, 1998, T cells recognizing leukemic CD34(+) progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukaemia after allogeneic stem cell transplantation, Proc Natl Acad Sci U S A, 95, 10152, 10.1073/pnas.95.17.10152
Drobyski, 1993, Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukaemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose, Blood, 82, 2310, 10.1182/blood.V82.8.2310.2310
Kolb, 1990, Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients, Blood, 76, 2462, 10.1182/blood.V76.12.2462.2462
Kolb, 1995, Graft-versus-leukaemia effect of donor lymphocyte transfusions in marrow grafted patients, Blood, 86, 2041, 10.1182/blood.V86.5.2041.bloodjournal8652041
Mar, 2011, The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis, Leukemia, 25, 1665, 10.1038/leu.2011.143
Dierks, 2008, Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation, Cancer Cell, 14, 238, 10.1016/j.ccr.2008.08.003
Irvine, 2009, Combination of the hedgehog pathway inhibitor LDE225 and nilotinib eliminates chronic myeloid leukemia stem and progenitor cells
Novartis Pharmaceuticals, 2012
Shah, 2014, Dasatinib plus smoothened (SMO) inhibitor BMS-833923 in chronic myeloid leukemia (CML) with resistance or suboptimal response to a prior tyrosine kinase inhibitor (TKI): phase I study CA180323, Blood, 124, 4539, 10.1182/blood.V124.21.4539.4539
Samanta, 2011, Janus kinase 2 regulates BCR-ABL signaling in chronic myeloid leukemia, Leukemia, 25, 463, 10.1038/leu.2010.287
Bewry, 2008, Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance, Mol Cancer Ther, 7, 3169, 10.1158/1535-7163.MCT-08-0314
Carlesso, 1996, Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines trans-formed by BCR/ABL, J Exp Med, 183, 811, 10.1084/jem.183.3.811
Warsch, 2013, JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia, Blood, 122, 2167, 10.1182/blood-2013-02-485573
Gallipoli, 2014, JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo, Blood, 124, 1492, 10.1182/blood-2013-12-545640
Iurlo, 2014, Imatinib and ruxolitinib association: first experience in two patients, Haematologica, 99, 10.3324/haematol.2013.102525
Knoche, 2012, Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib, Blood (ASH Annual Meeting Abstracts), 120, 2832
Neviani, 2005, The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein, Cancer Cell, 8, 355, 10.1016/j.ccr.2005.10.015
Perrotti, 2013, Protein phosphatase 2A: a target for anticancer therapy, Lancet Oncol, 14, e229, 10.1016/S1470-2045(12)70558-2
Neviani, 2007, FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia, J Clin Invest, 117, 2408, 10.1172/JCI31095
Agarwal, 2014, Antagonism of SET using OP449 enhances the efficacy of tyrosine kinase inhibitors and overcomes drug resistance in myeloid leukemia, Clin cancer Res, 20, 2092, 10.1158/1078-0432.CCR-13-2575
Yoshida, 1992, A novel tetrapeptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells, Jpn J Cancer Res, 83, 324, 10.1111/j.1349-7006.1992.tb00109.x
Nimmanapalli, 2003, Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells, Cancer Res, 63, 5126
Guilhot, 2008, A phase II study of oral panobinostat (LBH589) in accelerated phase (AP) or blast crisis (BC) chronic myeloid leukemia (CML) patients resistant to ≥2 BCR-ABL tyrosine kinase inhibitors, Blood, 112, 4263, 10.1182/blood.V112.11.4263.4263
Zaritskey, 2008, A phase II study of oral panobinostat (LBH589) for chronic phase chronic myeloid leukemia (CML) with resistance to ≥2 BCR-ABL tyrosine kinase inhibitors, Blood, 112, 4254, 10.1182/blood.V112.11.4254.4254
Carter, 2005, Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases, Proc Natl Acad Sci U S A, 102, 11011, 10.1073/pnas.0504952102
Seymour, 2014, A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, Blood Cancer J, 4, e238, 10.1038/bcj.2014.60
Pietarinen, 2015, Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing, Blood Cancer J, 5, e309, 10.1038/bcj.2015.30
Gumireddy, 2005, A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance, Proc Natl Acad Sci U S A, 102, 1992, 10.1073/pnas.0408283102
Wu, 2010, ON012380, a putative BCR-ABL kinase inhibitor with a unique mechanism of action in imatinib-resistant cells, Leukemia, 24, 869, 10.1038/leu.2009.300
Heidel, 2012, Genetic and pharmacologic inhibition of beta-catenin tar-gets imatinib-resistant leukemia stem cells in CML, Cell Stem Cell, 10, 412, 10.1016/j.stem.2012.02.017
Kantarjian, 2010, Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance, Cancer, 116, 2665
Sellers, 2015
Thiesing, 2000, Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl–positive cells, Blood, 96, 3195, 10.1182/blood.V96.9.3195
Kano, 2001, In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents, Blood, 97, 1999, 10.1182/blood.V97.7.1999
Guilhot, 2009, Interferon in chronic myeloid leukaemia : past and future, Best Pract Res Clin Haematol, 22, 315, 10.1016/j.beha.2009.10.005
Lipton, 2007, Phase II, randomized, multicenter, comparative study of peginterferon alfa-2a(40KD) versus interferon alfa -2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia, Leuk Lymphoma, 48, 497, 10.1080/10428190601175393
Michallet, 2004, Pegylated recombinant interferon alpha-2b vs recombinant interferon alpha-2b for the initial treatment of chronic-phase chronic myelogenous leukemia: a phase III study, Leukemia, 18, 309, 10.1038/sj.leu.2403217
Essers, 2009, IFNalpha activates dormant haematopoietic stem cells in vivo, Nature, 458, 904, 10.1038/nature07815
Sato, 2009, Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion, Nat Med, 15, 696, 10.1038/nm.1973
Bhattacharya, 2011, Bcr-abl signals to desensitize chronic myeloid leukemia cells to interferon alpha via accelerating the degradation of its receptor, Blood, 118, 4179, 10.1182/blood-2010-12-325373
Baccarani, 2004, Imatinib an pegylated human recombinant interferon-α2b in early chronic-phase chronic myeloid leukemia, Blood, 104, 4245, 10.1182/blood-2004-03-0826
Palandri, 2008, Front line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-α: 5 year outcome, Haematologica, 93, 770, 10.3324/haematol.12265
O'Brien, 2001, PEGIntron and STI571 combination evaluation study (PISCES) in chronic phase Chronic Myeloïd Leukemia, Blood, 98, 3512a
Preudhomme, 2010, Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia, N Engl J Med, 363, 2511, 10.1056/NEJMoa1004095
Johnson-Ansah, 2013, Tolerability and efficacy of pegylated interferon-α-2a in combination with imatinib for patients with chronic-phase chronic myeloid leukemia, Cancer, 119, 4284, 10.1002/cncr.28328
Guilhot, 2014, Blood, 124, 1793, 10.1182/blood.V124.21.1793.1793
Hehlmann, 2011, Tolerability-adapted imatinib 800 mg versus 400 mg versus. 400 mg + IFN in newly diagnosed chronic myeloid leukemia, J Clin Oncol, 29, 1634, 10.1200/JCO.2010.32.0598
Hehlmann, 2014, Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV, J Clin Oncol, 32, 415, 10.1200/JCO.2013.49.9020
Simonsson, 2011, Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia, Blood, 118, 3228, 10.1182/blood-2011-02-336685
Cortes, 2011, Cancer, 117, 572, 10.1002/cncr.25438
Nicolini, 2015, Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicenter, non randomized, open-label phase 2 study, Lancet, 2, e37
Hjorth-Hansen, 2016, Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients, Leukemia, 30, 1853, 10.1038/leu.2016.121
Roy, 2015, Combination of dasatinib and peg-interferon alpha 2b in chronic phase chronic myeloid leukemia (CP-CML) first line: preliminary results of a phase II trial, from the French Intergroup of CML (Fi-LMC), Blood, 126, 134, 10.1182/blood.V126.23.134.134
El Eit, 2013, Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha, Int J Cancer, 134, 988, 10.1002/ijc.28427
Guilhot, 2008, Immunotherapeutic approaches in chronic myelogenous Leukemia, Leukemia Lymphoma, 49, 629, 10.1080/10428190801927510
Bocchia, 1996, Specific human cellular immunity to BCR-ABL oncogene-derived peptides, Blood, 87, 3587, 10.1182/blood.V87.9.3587.bloodjournal8793587
Norbury, 2000, b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukemia, Br J Haematol, 109, 616, 10.1046/j.1365-2141.2000.02090.x
Livingston, 1994, Phase I trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma, Vaccine, 12, 1275, 10.1016/S0264-410X(94)80052-2
Cathcart, 2003, A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia, Blood, 103, 1037, 10.1182/blood-2003-03-0954
Bocchia, 2005, Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial, Lancet, 365, 657, 10.1016/S0140-6736(05)70931-4
Rojas, 2007, Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study, Leukemia, 21, 2287, 10.1038/sj.leu.2404858
Rezvani, 2008, Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies, Blood, 111, 236, 10.1182/blood-2007-08-108241
Quintarelli, 2008, Cytotoxic T lymphocytes directed to the preferentially expressed antigen of melanoma (PRAME) target chronic myeloid leukemia, Blood, 112, 1876, 10.1182/blood-2008-04-150045
Dubrovsky, 2014, A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL1 leukemias, Blood, 123, 3296, 10.1182/blood-2014-01-549022
Goff, 2013, A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition, Cell Stem Cell, 12, 316, 10.1016/j.stem.2012.12.011
Ko, 2014, The BCL2 inhibitor ABT-199 significantly enhances imatinib induced cell death in chronic myeloid leukemia progenitors, Oncotarget, 5, 9033, 10.18632/oncotarget.1925
Heiblig, 2014, Subcutaneous omacetaxine mepesuccinate in patients with chronic myeloid leukemia in tyrosine kinase inhibitor-resistant patients: review and perspectives, Leu Res, 38, 1145, 10.1016/j.leukres.2014.05.007
Prost, 2015, Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists, Nature, 10.1038/nature15248